Home › Companies › ALNYLAM PHARMACEUTICALS INC. › 2024-2025

ALNYLAM PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and ALNYLAM PHARMACEUTICALS INC.’s Form 8-K, filed May 13, 2025 (Item 5.07 on EDGAR). Page generated October 18, 2026.

8Reported items
589Asset managers
5,798Fund votes
May 8, 2025Meeting date

Results at a glance

Meeting of May 8, 2025: 8 items on ALNYLAM PHARMACEUTICALS INC.’s Form 8-K, filed May 13, 2025: 4 elected · 4 approved.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ALNYLAM PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by ALNYLAM PHARMACEUTICALS INC.

These tallies are ALNYLAM PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 13, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ALNYLAM PHARMACEUTICALS INC. — official shareholder meeting results, meeting held May 8, 2025
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Carolyn R. Bertozzi, Ph.D.	108,200,098	10,440,708	24,081	--	4,826,451	91%	Elected	—
Elect Director: Margaret A. Hamburg, M.D.	108,041,420	10,601,230	22,237	--	4,826,451	91%	Elected	—
Elect Director: Colleen F. Reitan	111,919,864	6,734,585	10,438	--	4,826,451	94%	Elected	—
Elect Director: Amy W. Schulman	103,753,055	14,370,696	541,136	--	4,826,451	88%	Elected	—
The terms of office of the following directors continued after the Annual Meeting: Dennis A. Ausiello, M.D.	111,515,553	7,120,857	28,477	--	4,826,451	94%	Approved	—
3. The Company's Second Amended and Restated 2018 Stock Incentive Plan	114,044,496	4,590,661	29,730	--	4,826,451	96%	Approved	—
4. In a non-binding advisory vote, the compensation of the Company's named executive officers	111,725,907	6,909,706	29,274	--	4,826,451	94%	Approved	—
5. The appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2025	117,032,947	6,405,215	53,176	--	0	95%	Approved	—

Source: ALNYLAM PHARMACEUTICALS INC., Form 8-K, filed with the SEC on May 13, 2025 — read the filing on EDGAR.

How asset managers voted at the ALNYLAM PHARMACEUTICALS INC. 2024-2025 meeting

Each item below shows how the 589 asset managers that disclosed a ALNYLAM PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ALNYLAM PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Amy W. Schulman

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%

FOR: 103,753,055AGAINST: 14,370,696

Details: description as filed, official tally, votes by 129 asset managers

Description as filed by funds: To elect the following nominees as Class III directors of Alnylam: Amy W. Schulman

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Amy W. Schulman”): 103,753,055 for, 14,370,696 against, per its Form 8-K filed May 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class III directors, each to serve until the Company's 2028 annual meeting of stockholders or until her successor is duly elected and qualified.”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 129 asset managers below reported 66,638,547 for, 7,187,268 against, 354,407 abstained.

FOR

FOR: 66,638,547AGAINST: 7,187,268ABSTAIN: 354,407

Largest asset managers voting on “To elect the following nominees as Class III directors of Alnylam: Amy W. Schulman” at ALNYLAM PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Capital Group	17,729,763	0	0	For
Vanguard	15,802,195	1	0	For
Fidelity	13,243,154	0	0	For
T. Rowe Price	0	5,284,540	0	Against
BlackRock	3,917,449	0	0	For
Dodge & Cox	2,572,141	0	0	For
AMCAP FUND	2,401,920	0	0	For
NEW ECONOMY FUND	1,607,880	0	0	For
JPMorgan	1,384,836	0	0	For
American Century	968,978	0	0	For
INVESTMENT CO OF AMERICA	908,741	0	0	For
Jackson National	368,014	432,844	0	Mixed
New York Life	734,703	0	0	For
TIAA	684,000	0	0	For
State Street	1,098	613,124	0	Against
Charles Schwab	531,740	0	0	For
Invesco	0	58,830	344,410	Mixed
Prudential/PGIM	252,073	0	0	For
MassMutual	26,477	193,472	0	Mixed
FRANKLIN STRATEGIC SERIES	198,352	0	0	For
Federated Hermes	192,849	0	0	For
CARILLON SERIES TRUST	190,489	0	0	For
Equitable	141,256	47,134	0	Mixed
First Trust	179,798	0	0	For
Victory Capital	176,464	0	0	For

Showing the 25 largest of 129 asset managers. See all 129 in the interactive database.

2. Elect Director: Carolyn R. Bertozzi, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%

FOR: 108,200,098AGAINST: 10,440,708

Details: description as filed, official tally, votes by 129 asset managers

Description as filed by funds: To elect the following nominees as Class III directors of Alnylam: Carolyn R. Bertozzi, Ph.D.

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Carolyn R. Bertozzi, Ph.D.”): 108,200,098 for, 10,440,708 against, per its Form 8-K filed May 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class III directors, each to serve until the Company's 2028 annual meeting of stockholders or until her successor is duly elected and qualified.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 129 asset managers below reported 67,688,379 for, 6,487,177 against, 4,666 abstained.

FOR

FOR: 67,688,379AGAINST: 6,487,177ABSTAIN: 4,666

Largest asset managers voting on “To elect the following nominees as Class III directors of Alnylam: Carolyn R. Bertozzi, Ph.D.” at ALNYLAM PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Capital Group	17,729,763	0	For
Vanguard	15,802,195	1	For
Fidelity	13,243,154	0	For
T. Rowe Price	0	5,284,540	Against
BlackRock	3,917,449	0	For
Dodge & Cox	2,572,141	0	For
AMCAP FUND	2,401,920	0	For
NEW ECONOMY FUND	1,607,880	0	For
JPMorgan	1,384,836	0	For
American Century	968,978	0	For
INVESTMENT CO OF AMERICA	908,741	0	For
Jackson National	368,014	432,844	Mixed
New York Life	734,703	0	For
TIAA	684,000	0	For
State Street	614,222	0	For
Charles Schwab	531,740	0	For
Invesco	403,240	0	For
Prudential/PGIM	252,073	0	For
MassMutual	26,477	193,472	Mixed
FRANKLIN STRATEGIC SERIES	198,352	0	For
Federated Hermes	192,849	0	For
CARILLON SERIES TRUST	190,489	0	For
Equitable	141,256	47,134	Mixed
First Trust	179,798	0	For
Victory Capital	176,464	0	For

Showing the 25 largest of 129 asset managers. See all 129 in the interactive database.

3. Elect Director: Colleen F. Reitan

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 111,919,864AGAINST: 6,734,585

Details: description as filed, official tally, votes by 129 asset managers

Description as filed by funds: To elect the following nominees as Class III directors of Alnylam: Colleen F. Reitan

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Colleen F. Reitan”): 111,919,864 for, 6,734,585 against, per its Form 8-K filed May 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class III directors, each to serve until the Company's 2028 annual meeting of stockholders or until her successor is duly elected and qualified.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 129 asset managers below reported 71,353,982 for, 2,821,574 against, 4,666 abstained.

FOR

FOR: 71,353,982AGAINST: 2,821,574ABSTAIN: 4,666

Largest asset managers voting on “To elect the following nominees as Class III directors of Alnylam: Colleen F. Reitan” at ALNYLAM PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Capital Group	17,729,763	0	For
Vanguard	15,802,195	1	For
Fidelity	13,243,154	0	For
T. Rowe Price	2,620,560	2,663,980	Mixed
BlackRock	3,917,449	0	For
Dodge & Cox	2,572,141	0	For
AMCAP FUND	2,401,920	0	For
NEW ECONOMY FUND	1,607,880	0	For
JPMorgan	1,384,836	0	For
American Century	968,978	0	For
INVESTMENT CO OF AMERICA	908,741	0	For
Jackson National	800,858	0	For
New York Life	734,703	0	For
TIAA	684,000	0	For
State Street	614,222	0	For
Charles Schwab	531,740	0	For
Invesco	403,240	0	For
Prudential/PGIM	252,073	0	For
MassMutual	215,509	4,440	For
FRANKLIN STRATEGIC SERIES	198,352	0	For
Federated Hermes	192,849	0	For
CARILLON SERIES TRUST	190,489	0	For
Equitable	141,256	47,134	Mixed
First Trust	179,798	0	For
Victory Capital	176,464	0	For

Showing the 25 largest of 129 asset managers. See all 129 in the interactive database.

4. Elect Director: Margaret A. Hamburg, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%

FOR: 108,041,420AGAINST: 10,601,230

Details: description as filed, official tally, votes by 129 asset managers

Description as filed by funds: To elect the following nominees as Class III directors of Alnylam: Margaret A. Hamburg, M.D.

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Margaret A. Hamburg, M.D.”): 108,041,420 for, 10,601,230 against, per its Form 8-K filed May 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class III directors, each to serve until the Company's 2028 annual meeting of stockholders or until her successor is duly elected and qualified.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 129 asset managers below reported 67,688,602 for, 6,486,954 against, 4,666 abstained.

FOR

FOR: 67,688,602AGAINST: 6,486,954ABSTAIN: 4,666

Largest asset managers voting on “To elect the following nominees as Class III directors of Alnylam: Margaret A. Hamburg, M.D.” at ALNYLAM PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Capital Group	17,729,763	0	For
Vanguard	15,802,195	1	For
Fidelity	13,243,154	0	For
T. Rowe Price	0	5,284,540	Against
BlackRock	3,917,449	0	For
Dodge & Cox	2,572,141	0	For
AMCAP FUND	2,401,920	0	For
NEW ECONOMY FUND	1,607,880	0	For
JPMorgan	1,384,836	0	For
American Century	968,978	0	For
INVESTMENT CO OF AMERICA	908,741	0	For
Jackson National	368,014	432,844	Mixed
New York Life	734,703	0	For
TIAA	684,000	0	For
State Street	614,222	0	For
Charles Schwab	531,740	0	For
Invesco	403,240	0	For
Prudential/PGIM	252,073	0	For
MassMutual	26,477	193,472	Mixed
FRANKLIN STRATEGIC SERIES	198,352	0	For
Federated Hermes	192,849	0	For
CARILLON SERIES TRUST	190,489	0	For
Equitable	141,256	47,134	Mixed
First Trust	179,798	0	For
Victory Capital	176,464	0	For

Showing the 25 largest of 129 asset managers. See all 129 in the interactive database.

5. To approve an Amendment to our Restated Certificate of Incorporation allowing for officer exculpation.

No official matchCORPORATE GOVERNANCE

Combines 3 wordings of this item as funds reported it.

96% of fund votes cast · no official result

FOR

Details: votes by 126 asset managers

The 126 asset managers below reported 71,426,204 for, 2,681,353 against, 4,666 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 71,426,204AGAINST: 2,681,353ABSTAIN: 4,666

Largest asset managers voting on “To approve an Amendment to our Restated Certificate of Incorporation allowing for officer exculpation.” at ALNYLAM PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Capital Group	17,729,763	0	For
Vanguard	15,757,815	44,381	For
Fidelity	13,243,154	0	For
T. Rowe Price	5,284,540	0	For
BlackRock	3,917,449	0	For
Dodge & Cox	2,572,141	0	For
AMCAP FUND	2,401,920	0	For
NEW ECONOMY FUND	1,607,880	0	For
JPMorgan	0	1,384,836	Against
American Century	968,978	0	For
INVESTMENT CO OF AMERICA	908,741	0	For
Jackson National	520,660	280,198	Mixed
New York Life	734,703	0	For
TIAA	684,000	0	For
State Street	614,172	50	For
Charles Schwab	531,740	0	For
Invesco	403,240	0	For
Prudential/PGIM	86,556	165,517	Mixed
MassMutual	193,472	26,477	Mixed
FRANKLIN STRATEGIC SERIES	198,352	0	For
Federated Hermes	0	192,849	Against
CARILLON SERIES TRUST	190,489	0	For
Equitable	67,083	121,307	Mixed
First Trust	179,798	0	For
Victory Capital	176,464	0	For

Showing the 25 largest of 126 asset managers. See all 126 in the interactive database.

6. 3. The Company's Second Amended and Restated 2018 Stock Incentive Plan

Official result Fund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%

FOR: 114,044,496AGAINST: 4,590,661

Details: description as filed, official tally, votes by 145 asset managers

Description as filed by funds: To approve the second amended and restated 2018 Stock Incentive Plan.

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“3. The Company's Second Amended and Restated 2018 Stock Incentive Plan”): 114,044,496 for, 4,590,661 against — passed, per its Form 8-K filed May 13, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the Company's Second Amended and Restated 2018 Stock Incentive Plan.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 127 asset managers voting on “To approve the second amended and restated 2018 Stock Incentive Plan.” at ALNYLAM PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Capital Group	17,729,763	0	For
Vanguard	15,802,196	0	For
Fidelity	13,243,154	0	For
T. Rowe Price	5,284,540	0	For
BlackRock	3,917,449	0	For
Dodge & Cox	2,572,141	0	For
AMCAP FUND	2,401,920	0	For
NEW ECONOMY FUND	1,607,880	0	For
JPMorgan	1,384,836	0	For
American Century	0	968,978	Against
INVESTMENT CO OF AMERICA	908,741	0	For
Jackson National	800,858	0	For
New York Life	734,703	0	For
TIAA	684,000	0	For
State Street	614,211	11	For
Charles Schwab	531,740	0	For
Invesco	403,240	0	For
Prudential/PGIM	113,597	138,476	Mixed
MassMutual	219,949	0	For
FRANKLIN STRATEGIC SERIES	198,352	0	For
Federated Hermes	192,849	0	For
CARILLON SERIES TRUST	190,489	0	For
Equitable	188,390	0	For
First Trust	179,798	0	For
Victory Capital	176,464	0	For

Fund voting reports, all 127 managers: 72,763,815 for, 1,357,401 against, 4,666 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 16 asset managers voting on “To approve the second amended and restated 2018 Stock Incentive Plan.” at ALNYLAM PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Orbis Allan Gray Ltd	1,319,195	0	For
Cardano Risk Management B.V.	27,773	0	For
Erste Asset Management GmbH	26,810	0	For
Integral Health Asset Management, LLC	10,646	0	For
Genus Capital Management Inc.	0	6,120	Against
UNITED CAPITAL FINANCIAL ADVISORS, LLC	1,890	0	For
OSSIAM	1,541	0	For
Maj Invest Holding A/S	517	0	For
Fortitude Family Office, LLC	500	0	For
ALGERT GLOBAL LLC	475	0	For
ANTIPODES PARTNERS Ltd	290	0	For
LEAVELL INVESTMENT MANAGEMENT, INC.	0	0	--
Boltwood Capital Management	30	0	For
Ballew Advisors, Inc	3	0	For
VOISARD ASSET MANAGEMENT GROUP, INC.	3	0	For
BRANDYWINE OAK PRIVATE WEALTH LLC	2	0	For

Institutional-manager reports, all 16 managers: 1,389,675 for, 6,120 against, 50 unknown.

7. 4. In a non-binding advisory vote, the compensation of the Company's named executive officers

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 24 wordings of this item as funds reported it.

94% Approved · of votes cast

FOR 94%

FOR: 111,725,907AGAINST: 6,909,706

Details: description as filed, official tally, votes by 589 asset managers

Description as filed by funds: To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“4. In a non-binding advisory vote, the compensation of the Company's named executive officers”): 111,725,907 for, 6,909,706 against — passed, per its Form 8-K filed May 13, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, in a non-binding advisory vote, the compensation of the Company's named executive officers.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports: 127 asset managers voting on “To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.” at ALNYLAM PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Capital Group	17,729,763	0	For
Vanguard	15,802,195	1	For
Fidelity	13,243,154	0	For
T. Rowe Price	5,145,659	138,881	For
BlackRock	3,917,449	0	For
Dodge & Cox	2,572,141	0	For
AMCAP FUND	2,401,920	0	For
NEW ECONOMY FUND	1,607,880	0	For
JPMorgan	1,384,836	0	For
American Century	0	968,978	Against
INVESTMENT CO OF AMERICA	908,741	0	For
Jackson National	800,858	0	For
New York Life	734,703	0	For
TIAA	684,000	0	For
State Street	614,222	0	For
Charles Schwab	531,740	0	For
Invesco	344,410	58,830	Mixed
Prudential/PGIM	252,073	0	For
MassMutual	219,949	0	For
FRANKLIN STRATEGIC SERIES	198,352	0	For
Federated Hermes	192,849	0	For
CARILLON SERIES TRUST	190,489	0	For
Equitable	188,390	0	For
First Trust	179,798	0	For
Victory Capital	176,464	0	For

Fund voting reports, all 127 managers: 72,578,042 for, 1,545,133 against, 4,666 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 490 asset managers voting on “To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.” at ALNYLAM PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Capital Group	16,859,224	0	For
Fidelity	14,080,586	0	For
T. Rowe Price	7,715,250	220,463	For
Capital Research Global Investors	7,118,387	0	For
BlackRock	4,618,851	0	For
Dodge & Cox	3,158,833	0	For
Wellington	2,943,019	0	For
State Street	2,881,125	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,282,770	0	For
Winslow Capital Management, LLC	2,140,323	0	For
JPMorgan	1,988,777	0	For
BAILLIE GIFFORD & CO LTD	1,454,257	0	For
American Century	0	1,422,398	Against
Orbis Allan Gray Ltd	1,319,195	0	For
BAILLIE GIFFORD OVERSEAS LTD	1,060,161	0	For
Northern Trust	758,135	0	For
Nuveen	694,473	0	For
Charles Schwab	604,543	0	For
Invesco	483,868	74,557	Mixed
Legal & General Investment Management Ltd	0	541,593	Against
Vanguard	523,069	0	For
Two Sigma	443,315	0	For
Loomis Sayles	436,175	0	For
PICTET ASSET MANAGEMENT SA	401,877	0	For
UBS	0	398,071	Against

Institutional-manager reports, all 490 managers: 83,480,787 for, 5,500,479 against, 40 abstained, 33,342 not voted, 50 unknown. Showing the 25 largest; see all in the interactive database.

8. 5. The appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%

FOR: 117,032,947AGAINST: 6,405,215

Details: description as filed, official tally, votes by 133 asset managers

Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2025.

ALNYLAM PHARMACEUTICALS INC.’s own tally for this item (“5. The appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2025”): 117,032,947 for, 6,405,215 against — passed, per its Form 8-K filed May 13, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment by the Company's Board of Directors of PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal year ending December 31, 2025.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 133 asset managers below reported 73,189,416 for, 986,391 against, 4,666 abstained.

FOR

FOR: 73,189,416AGAINST: 986,391ABSTAIN: 4,666

Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as ” at ALNYLAM PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Capital Group	17,729,763	0	For
Vanguard	15,037,144	765,052	For
Fidelity	13,243,154	0	For
T. Rowe Price	5,284,540	0	For
BlackRock	3,917,449	0	For
Dodge & Cox	2,572,141	0	For
AMCAP FUND	2,401,920	0	For
NEW ECONOMY FUND	1,607,880	0	For
JPMorgan	1,384,836	0	For
American Century	968,978	0	For
INVESTMENT CO OF AMERICA	908,741	0	For
Jackson National	800,858	0	For
New York Life	734,703	0	For
TIAA	684,000	0	For
State Street	614,200	22	For
Charles Schwab	531,740	0	For
Invesco	403,240	0	For
Prudential/PGIM	252,073	0	For
MassMutual	219,949	0	For
FRANKLIN STRATEGIC SERIES	198,352	0	For
Federated Hermes	192,849	0	For
CARILLON SERIES TRUST	190,489	0	For
Equitable	188,390	0	For
First Trust	179,798	0	For
Victory Capital	176,464	0	For

Showing the 25 largest of 133 asset managers. See all 133 in the interactive database.

Largest ALNYLAM PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 130,311,000 shares outstanding at the time of that meeting.

Fund voting reports: top ALNYLAM PHARMACEUTICALS INC. shareholders by shares voted on “To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive…”, 2024-2025
#	Asset manager	% of shares outstanding
1	Capital Group	13.61%
2	Vanguard	12.13%
3	Fidelity	10.16%
4	T. Rowe Price	4.06%
5	BlackRock	3.01%
6	Dodge & Cox	1.97%
7	AMCAP FUND	1.84%
8	NEW ECONOMY FUND	1.23%
9	JPMorgan	1.06%
10	American Century	0.74%

Institutional-manager reports: top ALNYLAM PHARMACEUTICALS INC. shareholders by shares voted on “To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive…”, 2024-2025
#	Asset manager	% of shares outstanding
1	Capital Group	12.94%
2	Fidelity	10.81%
3	T. Rowe Price	6.09%
4	Capital Research Global Investors	5.46%
5	BlackRock	3.54%
6	Dodge & Cox	2.42%
7	Wellington	2.26%
8	State Street	2.21%
9	GEODE CAPITAL MANAGEMENT, LLC	1.75%
10	Winslow Capital Management, LLC	1.64%

Reported ALNYLAM PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

ALNYLAM PHARMACEUTICALS INC. holdings and ownership disclosed for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
FMR (Fidelity)	11.75%	13F
Capital World Investors	8.38%	13G
BlackRock	7.34%	13F
Capital Research Global Investors	7.27%	13G
T. Rowe Price	2.69%	13F
State Street	2.58%	13F
Wellington Management	2.00%	13F
Norges Bank	1.76%	13F
JPMorgan Chase	1.70%	13F
Invesco	0.70%	13F

Percentages above are of 130,311,000 shares outstanding, as reported by ALNYLAM PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ALNYLAM PHARMACEUTICALS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At ALNYLAM PHARMACEUTICALS INC.'s shareholder meeting held May 8, 2025, in the 2024-2025 proxy season, 589 asset managers reported how they voted in their SEC Form N-PX filings, covering 5,798 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive… — ALNYLAM PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ALNYLAM PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 13, 2025.

ALNYLAM PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.